Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma.

作者: Natália Bertoni , Lied M. S. Pereira , Fábio E. Severino , Regina Moura , Winston B. Yoshida

DOI: 10.1186/S12881-015-0262-2

关键词: DiseaseComputational biologyGene expressionCancer researchHemangiomaGene regulatory networkGeneDruggabilitymicroRNAHuman geneticsBiology

摘要: Hemangioma is a common benign tumor in the childhood; however our knowledge about molecular mechanisms of hemangioma development and progression are still limited. Currently, microRNAs (miRNAs) have been shown as gene expression regulators with an important role disease pathogenesis. Our goals were to identify miRNA-mRNA networks associated infantile hemangioma. We performed meta-analysis previously published datasets including 98 samples. Deregulated genes further used potential Data integrated using bioinformatics methods, mapped proteins, which then construct protein-protein interaction networks. play roles cell growth differentiation, signaling, angiogenesis vasculogenesis. Regulatory identified included miR-9, miR-939 let-7 family; these showed most number interactions deregulated hemangioma, suggesting that they may disease. Additionally, results drug-gene druggable categories Drug-Gene Interaction Database. show microRNA-target be useful biomarkers for novel therapeutic strategies patients microRNA-regulated pathways potentially future

参考文章(97)
Joan Minguet, Katherine H. Smith, Carsten P. Bramlage, Peter Bramlage, Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives Cancer Chemotherapy and Pharmacology. ,vol. 76, pp. 219- 233 ,(2015) , 10.1007/S00280-015-2770-3
Philip M. Spanheimer, Allison W. Lorenzen, James P. De Andrade, Mikhail V. Kulak, Jennifer C. Carr, George W. Woodfield, Sonia L. Sugg, Ronald J. Weigel, Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. Annals of Surgical Oncology. ,vol. 22, pp. 4287- 4294 ,(2015) , 10.1245/S10434-015-4597-X
Liza C. Villaruz, Mark A. Socinski, The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update Current Oncology Reports. ,vol. 17, pp. 26- 26 ,(2015) , 10.1007/S11912-015-0448-Y
Filippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, Christian Cotsoglou, Flavia Melotti, Giuseppe Fanetti, Federica Perrone, Pamela Biondani, Cecilia Muscarà, Maria Di Bartolomeo, Jorgelina Coppa, Claudia Maggi, Massimo Milione, Elena Tamborini, Filippo de Braud, Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases Medical Oncology. ,vol. 32, pp. 182- ,(2015) , 10.1007/S12032-015-0638-3
Maria E. Cabanillas, Martin Schlumberger, Barbara Jarzab, Renato G. Martins, Furio Pacini, Bruce Robinson, Judith C. McCaffrey, Manisha H. Shah, Donald L. Bodenner, Duncan Topliss, Corina Andresen, James P. O'Brien, Min Ren, Yasuhiro Funahashi, Roger Allison, Rossella Elisei, Kate Newbold, Lisa F. Licitra, Steven I. Sherman, Douglas W. Ball, A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. ,vol. 121, pp. 2749- 2756 ,(2015) , 10.1002/CNCR.29395
Kotoe Takayoshi, Kosuke Sagara, Keita Uchino, Hitoshi Kusaba, Naotaka Sakamoto, Atsushi Iguchi, Eishi Baba, A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer. ,vol. 15, pp. 426- 426 ,(2015) , 10.1186/S12885-015-1443-2
T. Dragovich, D. Laheru, F. Dayyani, V. Bolejack, L. Smith, J. Seng, H. Burris, P. Rosen, M. Hidalgo, P. Ritch, A. F. Baker, N. Raghunand, J. Crowley, D. D. Von Hoff, Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) Cancer Chemotherapy and Pharmacology. ,vol. 74, pp. 379- 387 ,(2014) , 10.1007/S00280-014-2499-4
R. Chugh, K.A. Griffith, E.J. Davis, D.G. Thomas, J.D. Zavala, G. Metko, B. Brockstein, S.D. Undevia, W.M. Stadler, S.M. Schuetze, Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model Annals of Oncology. ,vol. 26, pp. 1459- 1464 ,(2015) , 10.1093/ANNONC/MDV171